Simm Peter J, Bicknell-Royle Jillian, Lawrie Jock, Nation Judy, Draffin Kellie, Stewart Karen G, Cameron Fergus J, Scheffer Ingrid E, Mackay Mark T
Royal Children's Hospital Melbourne, Australia; Murdoch Childrens Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Australia.
Royal Children's Hospital Melbourne, Australia.
Epilepsy Res. 2017 Oct;136:62-66. doi: 10.1016/j.eplepsyres.2017.07.014. Epub 2017 Jul 26.
The ketogenic diet (KD) is a medically supervised, high fat, low carbohydrate and restricted protein diet which has been used successfully in patients with refractory epilepsy. Only one published report has explored its effect on the skeleton. We postulated that the KD impairs skeletal health parameters in patients on the KD. Patients commenced on the KD were enrolled in a prospective, longitudinal study, with monitoring of Dual-energy X-ray absorptiometry (DXA) derived bone parameters including bone mineral content and density (BMD). Areal BMD was converted to bone mineral apparent density (BMAD) where possible. Biochemical parameters, including Vitamin D, and bone turnover markers, including osteocalcin, were assessed. Patients were stratified for level of mobility using the gross motor functional classification system (GMFCS). 29 patients were on the KD for a minimum of 6 months (range 0.5-6.5 years, mean 2.1 years). There was a trend towards a reduction in lumbar spine (LS) BMD Z score of 0.1562 (p=0.071) per year and 20 patients (68%) had a lower BMD Z score at the end of treatment. While less mobile patients had lower baseline Z scores, the rate of bone loss on the diet was greater in the more mobile patients (0.28 SD loss per year, p=0.026). Height adjustment of DXA data was possible for 13 patients, with a mean reduction in BMAD Z score of 0.19 SD. Only two patients sustained fractures. Mean urinary calcium-creatinine ratios were elevated (0.77), but only 1 patient developed renal calculi. Children on the KD exhibited differences in skeletal development that may be related to the diet. The changes were independent of height but appear to be exaggerated in patients who are ambulant. Clinicians should be aware of potential skeletal side effects and monitor bone health during KD treatment. Longer term follow up is required to determine adult/peak bone mass and fracture risk throughout life.
生酮饮食(KD)是一种在医学监督下的高脂肪、低碳水化合物和蛋白质受限饮食,已成功应用于难治性癫痫患者。仅有一篇已发表的报告探讨了其对骨骼的影响。我们推测生酮饮食会损害采用该饮食疗法患者的骨骼健康参数。开始采用生酮饮食的患者被纳入一项前瞻性纵向研究,监测双能X线吸收法(DXA)得出的骨参数,包括骨矿物质含量和密度(BMD)。在可能的情况下,将面积骨密度转换为骨矿物质表观密度(BMAD)。评估了包括维生素D在内的生化参数以及包括骨钙素在内的骨转换标志物。使用粗大运动功能分类系统(GMFCS)对患者的活动水平进行分层。29例患者采用生酮饮食至少6个月(范围0.5 - 6.5年,平均2.1年)。腰椎(LS)骨密度Z值每年有下降0.1562的趋势(p = 0.071),20例患者(68%)在治疗结束时骨密度Z值较低。虽然活动较少的患者基线Z值较低,但活动较多的患者饮食期间的骨质流失率更高(每年损失0.28标准差,p = 0.026)。13例患者的DXA数据可以进行身高校正,骨矿物质表观密度Z值平均降低0.19标准差。仅有2例患者发生骨折。尿钙 - 肌酐平均比值升高(0.77),但只有1例患者出现肾结石。采用生酮饮食的儿童在骨骼发育方面表现出差异,这可能与饮食有关。这些变化与身高无关,但在能行走的患者中似乎更为明显。临床医生应意识到潜在的骨骼副作用,并在生酮饮食治疗期间监测骨骼健康。需要进行更长时间的随访,以确定成年期/峰值骨量以及一生的骨折风险。